Biomarkers of Neurological Diseases and iPS Cell-Based Disease Research

Biomarkers of Neurological Diseases and iPS Cell-Based Disease Research - Biomarkers of Neurological Diseases and iPS Cell Research

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000052697

Enrollment

1000

Registered

2023-11-05

Start date

2023-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neurological Diseases

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with neurodegenerative diseases who received treatment at Keio University Hospital between October 1, 2022 and March 30, 2032 will be eligible for this study. The subjects must agree to participate in this study. Subjects must be at least 18 years of age. If it is difficult to obtain consent from the subject himself/herself at the time of obtaining consent due to a consciousness disorder, dementia, mental retardation, etc., consent will be obtained from a surrogate. The physician in charge selects a person who is considered to be able to represent the patient's presumed will and interests as a surrogate consentee, taking into consideration the patient's family structure, circumstances, and other factors.

Exclusion criteria

Exclusion criteria: Those who did not agree to participate in this study.

Design outcomes

Primary

Measure	Time frame
This research is expected to establish diagnostic methods for fluid biomarkers of neurodegenerative diseases and to develop drugs using iPS cells.	—

Countries

Japan

Contacts

Public ContactDAISUKE Ito

Keio University School of Medicine Department of Physiology/Memory center

dito@keio.jp0353633747

Outcome results